A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
Status:
COMPLETED
Trial end date:
2025-02-13
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-blind, placebo-controlled, ascending single oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects.